Police & Firemen s Retirement System of New Jersey Acquires 342 Shares of West Pharmaceutical Services, Inc. $WST

Police & Firemen s Retirement System of New Jersey boosted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,873 shares of the medical instruments supplier’s stock after acquiring an additional 342 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in West Pharmaceutical Services were worth $2,379,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in WST. Zions Bancorporation National Association UT purchased a new position in shares of West Pharmaceutical Services in the 1st quarter worth approximately $25,000. Quarry LP bought a new stake in West Pharmaceutical Services in the first quarter worth $27,000. CVA Family Office LLC boosted its stake in West Pharmaceutical Services by 573.3% during the second quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 172 shares during the period. Cromwell Holdings LLC increased its position in West Pharmaceutical Services by 587.5% during the second quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after acquiring an additional 188 shares during the last quarter. Finally, Brooklyn Investment Group raised its stake in shares of West Pharmaceutical Services by 83.3% in the first quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier’s stock valued at $61,000 after acquiring an additional 125 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Down 0.9%

Shares of NYSE WST opened at $260.08 on Wednesday. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $348.90. The firm has a market capitalization of $18.71 billion, a price-to-earnings ratio of 38.53, a PEG ratio of 4.09 and a beta of 1.08. The stock has a 50 day moving average price of $269.06 and a 200 day moving average price of $242.69. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. During the same period in the previous year, the company posted $1.85 EPS. West Pharmaceutical Services’s revenue was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Sell-side analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

Analyst Ratings Changes

WST has been the topic of several analyst reports. UBS Group upped their price target on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a report on Friday, October 24th. Barclays boosted their target price on West Pharmaceutical Services from $275.00 to $325.00 and gave the company an “equal weight” rating in a research report on Monday, October 27th. TD Cowen assumed coverage on West Pharmaceutical Services in a report on Wednesday, October 29th. They issued a “buy” rating and a $350.00 price target on the stock. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Tuesday, October 14th. Finally, KeyCorp upped their price objective on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $349.20.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.